Recce Pharmaceuticals Ltd RECEF
Set alert
At close · Oct 30
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.60
- Prev close
- 0.22
- Mkt cap
- 67.27M
- Vol
- 60
- Avg vol
- 0
- EPS
- -0.06
- P/E
- 0.00
More statistics
- Low
- 0.60
- High
- 0.60
News
1 week ago proactiveinvestors.com
Recce Pharmaceuticals signs Arrotex deal for RECCE 327 in Australia and New Zealand
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has signed an exclusive licensing and commercialisation agreement with Arrotex Pharmaceuticals for RECCE® 327 topical gel in Australia and New Zealand,…
1 week ago proactiveinvestors.com
Recce Pharmaceuticals advances Phase 3 diabetic foot infection trial to independent data review
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has reached a key milestone in its pivotal Phase 3 diabetic foot infection trial, with an independent Data Monitoring Committee (DMC) set to review…
1 month ago proactiveinvestors.com
Snowflake shares surge after Q2 beat, raised guidance
Snowflake Inc (NYSE:SNOW) shares jumped 23% in after-hours trading Wednesday after the cloud data company posted second-quarter results that beat Wall...
2 months ago proactiveinvestors.com
Polymarket valuation hits $21bn as Trump Jr's firm leads $1bn round
Polymarket, the blockchain-based prediction-market platform, is raising $1 billion in a new funding round that values the company at $21 billion on a...
2 months ago proactiveinvestors.com
Baidu misses Q2 revenue and earnings estimates as core business slips
Baidu.com (NASDAQ:BIDU) shares fell 9.3% in Tuesday morning trading after the Chinese tech giant reported second-quarter results that missed analyst...
3 months ago proactiveinvestors.com
Bank of England holds rates but three dissenters vote for hike
The Bank of England held interest rates at 3.75% but three policymakers voted for an increase as renewed tensions in the Middle East raised the risk of...
3 months ago proactiveinvestors.com
Recce Pharmaceuticals positioned for US$66.9 billion US biodefence strategy
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) is positioned to benefit from a new five-year, US$66.9 billion US Government strategy aimed at strengthening...
3 months ago proactiveinvestors.com
Recce Pharmaceuticals advances dual Phase 3 programs and MENA licensing strategy in strong June quarter
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) advanced its diabetic foot infection treatment toward commercialisation during the June quarter, securing...
3 months ago proactiveinvestors.com
Twilio faces higher bar heading into quarterly earnings, says Jefferies
Twilio Inc (NYSE:TWLO) is expected to deliver second quarter results that exceed expectations on revenue and operating income, with investors likely to...
3 months ago proactiveinvestors.com
Halliburton tops Q2 earnings estimates as CEO warns of softer oilfield services market
Halliburton Company (NYSE:HAL, XETRA:HAL) reported second quarter results that exceeded Wall Street expectations, but shares fell more than 6% after...
3 months ago proactiveinvestors.com
Recce Pharmaceuticals extends share purchase plan deadline to July 24
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has extended the closing date of its share purchase plan (SPP) to 5:00pm AEST on Friday, July 24, giving...
3 months ago proactiveinvestors.com
Recce patent extends Vietnam protection to 2041 - ICYMI
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) earlier this week strengthened its intellectual property position in Southeast Asia after securing a...
3 months ago proactiveinvestors.com
Amazon seen well-positioned going into Q2 report on AWS momentum, Prime Day spending
Amazon.com Inc (NASDAQ:AMZN) is well-positioned heading into its second-quarter earnings report, according to Jefferies, which reiterated the e-commerce and...
3 months ago proactiveinvestors.com
Dow dips but Nasdaq higher after soft CPI and good bank earnings offset IBM shocker
12:00pm: 'Benign' inflation print LPL Financial chief economist Jeffrey Roach said June's cooler-than-expected inflation report was largely driven by a...
3 months ago proactiveinvestors.com
Crypto's landmark Clarity Act stalls in Senate as passage odds sink to 39%
Prediction market traders now put the chances of the Clarity Act becoming law this year at just 39%, down sharply from a peak above 80% in February. The...
3 months ago proactiveinvestors.com
Small Cap Watch: biotech, gold and critical minerals explorers deliver key milestones
The S&P/ASX Small Ordinaries Index (ASX:XSO) slipped 25.1 points, or 0.74%, to 3,367.6, extending its five-day decline to 1.68% as weakness across the...
4 months ago proactiveinvestors.com
Recce Pharmaceuticals bolsters cash position with A$3.67 million tax refund ahead of Phase 3 milestones
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has strengthened its balance sheet with the receipt of a A$3.67 million income tax refund from the Australian...
4 months ago proactiveinvestors.com
Panmure Liberum says wine takeover exposes deep value at Naked and Virgin
Panmure Liberum has argued that a take-private bid for Sweden's Viva Wine Group lays bare how cheaply the UK's direct-to-consumer wine companies are...
4 months ago proactiveinvestors.com
Recce raises A$4M as it advances anti-infective trials and commercial licensing plans; another $4M to come in SPP
Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) has raised A$4 million to support commercial licensing activity, clinical trials and regulatory-enabling work...
4 months ago proactiveinvestors.com
Nasdaq set to take another hit from rotation out of tech before quarter-end
US stocks are set for another difficult session on Friday, with the Nasdaq on course for a fifth straight day of losses as investors continue to rotate out...